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Abstract 
 
The opioid epidemic is a growing public health 
emergency in the United States, with deaths from 
opioid overdose having increased five-fold since 1999. 
Emergency departments (EDs) are the primary sites of 
medical care after near-fatal opioid overdose but are 
poorly equipped to provide adequate substance use 
treatment planning prior to discharge. In many 
underserved locales, limited access to clinicians 
trained in addiction medicine and behavioral health 
exacerbates this disparity. In an effort to improve post-
overdose care in the ED, we developed a telemedicine 
protocol to facilitate timely access to substance use 
disorder evaluations. In this paper, we describe the 
conception and refinement of the telemedicine 
program, our experience with the first 20 participants, 
and potential implications of the platform on health 
disparities for individuals with opioid use disorder.   
 
 
1. Introduction  
 
The death toll from the opioid epidemic continues 
to rise, with 47,600 individuals in the United States of 
America dying from opioid overdose in 2017, a 43.8% 
increase from 2015 [1, 2]. Emergency departments 
(EDs) represent the primary sites of medical care after 
opioid overdose, but often are ill-equipped to provide 
adequate substance use treatment referrals prior to a 
patient’s discharge. This results in a cycle of 
successive resuscitations from overdose followed by 
discharges, often culminating in a final fatal overdose  
[3, 4].  
Disparities in access to healthcare, health 
behaviors, and health outcomes are well documented 
between populations in rural areas and their urban 
counterparts [5-7]. These differences persist even 
when considered independently of race/ethnicity and 
socioeconomic status [8]. People who use drugs 
(PWUD) are another medically underserved 
population that is at risk for adverse health outcomes 
[9-11]. The subset of PWUD residing outside of major 
urban centers thus represents a particularly high-risk 
group at a significant health disadvantage [11, 12]. 
Therefore, there is a critical need to address the health 
inequity that leads to disproportionate morbidity and 
mortality risk among PWUD in rural areas.  
To address the opioid epidemic, the state of 
Massachusetts enacted legislation in 2016 mandating 
that individuals presenting to the ED after suspected 
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opioid overdose be offered a Substance Use Disorder 
Evaluation (SUDE) [13]. This targeted, 20-minute 
intervention conducted by a behavioral health 
clinician is adapted from the evidence-based 
Screening, Brief Interview and Referral to Treatment 
(SBIRT), and identifies individual patterns of 
substance use, details appropriate level of addiction 
care, and motivates patients to seek treatment [13, 14]. 
As EDs in Massachusetts and in other states seek to 
improve the care they provide to PWUD, they face a 
critical limitation in that a qualified clinician trained in 
the treatment of opioid use disorder may not be 
available in a timely fashion during the post-overdose 
period [15]. This issue is exacerbated in rural and 
underserved areas. 
 Ideally, an individual who is assessed in the ED 
for opioid overdose would have ready access to a 
behavioral health clinician who can help devise a 
collaborative long-term treatment plan. However, the 
limited availability of addiction medicine resources 
often results in unintended delays that can lead a 
frustrated patient to decline a SUDE and leave the 
hospital without so much as a discussion of evidence-
based therapies such as MAT (e.g., opioid agonist 
therapy with methadone or partial agonist therapy with 
buprenorphine or Suboxone®) [16, 17]. This is a 
critical missed opportunity; individuals who are 
successfully revived with naloxone following an 
opioid overdose are at high risk of death within the 
subsequent year [18]. Therefore, the ED visit after a 
near-fatal overdose represents an opportunity to bridge 
this vulnerable population to long-term treatment; a 
failure to intervene during this critical time carries 
significant mortality risk.  
Telemedicine represents a promising solution to 
these missed opportunities. A recent review found that 
telemedicine may have equivalent outcomes as 
compared to in-person services for indications such as 
mental health and rehabilitation [19]. However, the 
application of telemedicine specifically to substance 
use disorder treatment is not as well studied; one study 
found that utilization rates appear to be increasing, but 
overall remain very low [20]. Prior work has 
characterized the use of telemedicine by organizations 
that provide outpatient care for substance use disorder 
as being primarily in the form of computerized 
screening programs, telephone-based recovery 
support systems, and telephone-based therapy [21]. 
There is demonstrated interest from addiction 
medicine clinicians in developing videoconferencing 
for the provision of substance use disorder treatment, 
but there are anticipated barriers to implementation, 
including concerns of startup costs, lack of 
reimbursement for services, unfamiliarity with 
technology, inexperience with telemedicine, and 
confidentiality concerns [22]. 
Telemedicine in the ED setting is perhaps most 
familiar in the form of videoconferencing for time-
sensitive neurologic emergencies, such as suspected 
acute cerebrovascular accidents (strokes) [23]. In the 
present study, we sought to extend the impact of ED-
based telemedicine to the treatment of opioid use 
disorder by developing a telemedicine-based 
substance use disorder evaluation (teleSUDE) 
platform, and to gather preliminary data regarding its 
feasibility and usability. The ultimate goal of 
teleSUDE is to provide immediate, timely access to an 
addiction medicine clinician in EDs where an in-
person evaluation may not be logistically possible. 
 
2. TeleSUDE technology platform  
 
We envisioned teleSUDE as a system that would 
be familiar, intuitive, and easy to use for both clinician 
and patient. To this end, we obtained a pair of matched 
Apple iPad Pro tablet computers (San Jose, CA, USA) 
equipped with Zoom (San Jose, CA, USA), a Health 
Insurance Portability and Accountability Act 
(HIPAA)-compliant software backbone that is device 
and operating system agnostic.  
The tablet computer was secured to a JACO mobile 
tablet cart equipped with a battery pack (Franklin, 
MA, USA) (Figure 1). When a teleSUDE clinician 
activates Zoom, an encrypted video conference call 
similar to “FaceTime” was made to the paired tablet 
computer accessed by the patient (Figure 2). A split 
screen allowed clinicians and patients to see each other 
in real-time throughout the duration of the 
telemedicine encounter (Figure 3).  
The SUDE clinician was given a standardized 20-
minute training on how to operate teleSUDE as well 
as troubleshoot issues with connectivity, potential loss 
of video and voice streams, and techniques to re-
establish the teleSUDE in the instance of lost 
connectivity. The clinician demonstrated competency 
operating teleSUDE by completing mock evaluations 
with trained members of the study team. 
 
3. Design considerations  
 
To enhance portability in a busy ED environment, 
we elected to use a pair of matched tablet computers 
equipped with WiFi connectivity as the backbone for 
our teleSUDE platform. We sought to maximize 
usability and minimize startup costs by utilizing 
existing consumer-grade tablet computers, rather than 
purchasing specialized medical teleconferencing 
equipment, which is often unwieldy and expensive. 
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Figure 1. TeleSUDE apparatus consisting of 
an Apple iPad Pro tablet computer mounted 
on a locking JACO mobile tablet cart. 
 
 
Figure 2. Schematic representation of 
teleSUDE protocol. 
 
Figure 3. Screen capture demonstrating the 
functionality of the teleSUDE protocol during 
a simulated encounter between study staff. 
 
We selected Apple tablet computers over other 
similar devices because of their ubiquity and uniform 
user interface, as well as predictable product support 
cycles. We felt that Apple’s iOS offered a distinct 
advantage over other operating systems, which can 
suffer from version fragmentation and inconsistent 
user experiences due to proprietary graphic user 
interface overlays.  
By using a telemedicine suite that is device and 
operating system agnostic, teleSUDE will have 
maximum flexibility and scalability, as it will not be 
limited to a hospital’s specific computer systems. The 
only requirement for delivering teleSUDE will be a 
WiFi connection, which is ubiquitous in modern 
hospitals. 
Initially, we had intended to use the tablet 
computer’s integrated speaker and microphone for 
participant encounters in a similar fashion to devices 
currently in use at our institution for acute neurologic 
emergencies, however it became apparent based on 
early feedback from the teleSUDE clinician and study 
participants that incorporating over-the-ear 
headphones with a microphone may be a better 
solution. This had the enhanced benefit of ensuring an 
additional level of privacy and protection of sensitive 
health information, which may encourage patients to 
be more candid regarding their substance use. 
 
4. Methods  
 
Prior to initiation of the study protocol, teleSUDE 
was assembled and deployed in our ED using mock 
encounters with study staff. Field testing was 
performed by study staff using paired tablet computers 
within various patient care areas at our institution, with 
attention to connectivity in areas where interference 
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may arise (e.g. in the vicinity of cardiac telemetry 
monitors, diagnostic radiology studies, cellular phone 
use by patients and clinicians). Once we confirmed 
functionality, we initiated study enrollment. 
This was a single arm, prospective observational 
study approved by the University of Massachusetts 
Medical School Institutional Review Board. A 
convenience sample of participants presenting to the 
ED after a known or suspected opioid overdose was 
utilized. Participants were eligible for the study if they 
received naloxone (the antidote for opioid overdose) 
in the pre-hospital or ED setting, were 18 years of age 
or older, English-speaking, and able to provide 
informed consent. Potential subjects were excluded if 
they were pregnant, prisoners or in police custody, or 
presenting with a primary psychiatric complaint.  
Once a potential participant was deemed eligible, 
they were approached and enrolled by a member of the 
study team. Individuals who declined to participate 
received the standard of care, an in-person encounter 
with a SUDE clinician. Participants who consented 
were given a brief overview of the teleSUDE platform 
and provided with the opportunity to ask questions. 
Participants then received their SUDE via the 
telemedicine interface.  
At the conclusion of the telemedicine encounter, 
study staff administered a brief survey based on the 
technology acceptance model framework regarding 
participant attitudes toward and acceptance of the 
technology artifact [24]. Study staff then probed 
further regarding the participant’s overall experience. 
Once the participant encounter was completed, study 
staff prepared a debrief summarizing key points that 
arose during the intervention. Study staff also 
followed up with the teleSUDE clinician to obtain 
feedback regarding their overall perception on how the 
encounter went and if any technical errors arose. 
 
5. Results  
 
5.1. Participant characteristics 
  
Twenty-seven individuals were approached to 
participate. Twenty consented to participate in our 
pilot study, and seven declined. Median age was 32 
years, 13 participants identified as male, and 15 
participants identified as Caucasian. Demographic 
characteristics of participants can be found in Table 1. 
The individuals who declined to participate cited a 
general dislike of technology (N=2), a lack of interest 
in receiving a SUDE (N=1), and an unwillingness to 
partake in a research study (N=4). Nineteen of the 20 
participants who consented completed their SUDE via 
telemedicine. The remaining individual consented to 
participate, but was unable to complete the study 
protocol because the tablet computer’s battery was 
depleted. 
 
Table 1. Demographic characteristics of 
participants. 
 N=20 
Median age, years (IQR) 32 (30, 48) 
  
Sex  
  Male 13 
  Female 7 
Ethnicity/Race  
  White, non-Hispanic 15 
  Black, non-Hispanic 1 
  Hispanic 2 
  Other 2 
 
5.2. Participant perceptions of usability and 
acceptability 
 
Sixteen participants responded to the post-
encounter survey regarding teleSUDE’s usability and 
acceptability (Table 2). Unfortunately, three 
participants did not complete the survey for the 
following reasons: time-sensitive requirements of 
another research study (1), significant restlessness and 
inability to concentrate (1), and survey responses 
failing to sync properly (1). However, study staff did 
record informal notes regarding these three 
participants’ attitudes toward teleSUDE. 
The technology was favorably reviewed by all 
study participants, with two subjects describing the 
technology artifact as “cool” and one going so far as 
to state that teleSUDE is the “best thing since sliced 
bread and bacon, and I’m a Georgia boy so I love 
bacon.” Participants were unanimous in rating the 
technology as easy to use and found the audio and 
video quality to be satisfactory, despite two 
participants describing pre-existing “hearing 
problems” and one stating they were “legally blind 
without glasses.” Three participants stated that they 
would prefer telemedicine over an in-person 
encounter, including one who admitted they were “not 
a tech person” but cited teleSUDE’s advantages as 
being “quick, convenient, and private.” Three 
participants commented that they would prefer an in-
person encounter, though they still found the 
telemedicine encounter satisfactory. The majority 
reported that they thought teleSUDE felt similar to 
having an in-person encounter. Two participants noted 
that the location of the camera on the tablet computer 
(to the left of the screen rather than above the screen 
in the midline) gave the appearance that the clinician 
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was looking elsewhere during the encounter, and that 
this made the encounter feel less personal than it 
otherwise could have been. 
 
Table 2. Participant responses to usability 
and acceptability survey. 
Characteristic (N=16) 
Agree  
No. (%) 
Strongly 
Agree 
No. (%) 
Amenable to having SUDE 
via telemedicine 
6 (38) 10 (62) 
TeleSUDE was easy to use  7 (44) 9 (56) 
Interacting with clinician 
via telemedicine felt similar 
to an in-person interaction  
7 (44) 8 (50) 
Quality of audio was 
satisfactory  
4 (27) 11 (73) 
Quality of video was 
satisfactory  
9 (56) 7 (44) 
Felt assured that the 
assessment was confidential 
6 (38) 10 (62) 
 
5.3. Clinician feedback 
 
The teleSUDE clinician reported that the 
technology was easy to use and that interacting with 
participants through telemedicine was similar to 
evaluating patients in person. The clinician did note 
significant ambient noise during three encounters, 
with the noise level becoming a distraction in two of 
these. This was mitigated in subsequent encounters by 
the use of over-ear headphones equipped with 
directional microphones, which markedly decreased 
transmission of noise from adjacent care areas.  
 
5.4. Technology-related issues 
 
A major technical failure occurred during one of 
the encounters when a participant who consented to 
the study protocol was unable to complete the 
telemedicine encounter because the tablet computer’s 
battery had not been recharged and was fully depleted.  
Minor technical difficulties were identified during 
three (15%) of the encounters. These consisted of brief 
latency issues with the video stream that both parties 
felt were insignificant and did not impact the flow of 
the evaluation. During another encounter, the video 
feed of the clinician failed to display on the 
participant’s tablet; this was quickly resolved by 
terminating the session and initiating a new one. 
Overall, the quality of the video conference was 
deemed satisfactory during all completed encounters.  
 
6. Discussion  
 
In this investigation, we gathered formative 
evidence that a low-intensity, affordable telemedicine 
platform is a feasible and acceptable way to conduct 
sensitive substance use disorder evaluations in the 
emergency department. Participants were able to 
operate the technology, and we were able to efficiently 
train a clinician to use teleSUDE. These data are 
significant because they demonstrate that first, patients 
who have overdosed on opioids are accepting of a 
telemedicine platform to conduct SBIRT evaluations, 
and second, the technology platform is a viable 
solution in the dynamic emergency department 
environment.  
While telemedicine has been used previously to 
provide psychiatric evaluations, this study represents 
the first time that it has been leveraged to provide 
substance use disorder evaluations for patients in the 
ED after near-fatal overdose [25, 26]. Participants 
were agreeable to the use of telemedicine, and most 
found it equivalent (or in some cases preferable) to 
standard in-person evaluations. This finding is 
reflected in other ED-based telemedicine programs, 
such as a study from our institution using Google 
Glass technology to provide remote dermatology 
consultation in the ED [27].  
We experienced only one major technical failure 
during our pilot, in which the telemedicine encounter 
could not be completed because the tablet computer’s 
battery was depleted. We subsequently modified our 
study protocol to ensure that all devices would be 
adequately recharged following use. Otherwise, we 
found that technological difficulties were generally 
minor and centered around transmission of ambient 
noise as well as brief network interruptions. We found 
that the first was easily remedied by utilizing 
headphones with directional microphones and that the 
second was essentially a non-issue.  
Given the societal stigma that persists regarding 
substance use disorder, PWUD understandably have 
significant concerns regarding preservation of privacy. 
Indeed, this has been demonstrated in rural areas with 
small close-knit communities, where individuals have 
reported not seeking care at treatment centers because 
their entire town will then be aware of their substance 
use disorder [28]. Our participants reported feeling 
assured that the teleSUDE assessment was private and 
confidential. This finding suggests that telemedicine 
may represent a unique solution to this issue: utilizing 
an encrypted HIPAA-compliant videoconferencing 
suite may allow PWUD in rural environments to 
access care for opioid use disorder in a secure and 
discreet manner. 
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This pilot program demonstrates that teleSUDE 
can be used to enhance the availability of substance 
use disorder counseling and treatment in patients 
presenting for evaluation after near-fatal overdose. 
Engaging PWUD to understand factors leading to 
acceptance or non-acceptance of telemedicine 
interventions is essential to the development of a 
scalable platform for providing addiction care 
resources.   
 
6.1. Limitations 
  
The limitations of our small pilot study are as 
follows. The study was aimed at assessing the 
feasibility and acceptability of using a telemedicine 
platform to deliver SUDEs to PWUD in a single high-
volume ED. The opinions of our limited number of 
participants may not be generalizable to the population 
of PWUD at large. Additionally, the resources 
available and the clinical environment at our academic 
tertiary care hospital are unlikely to be representative 
of the settings where teleSUDE would ultimately be 
utilized (e.g. community hospitals or rural critical 
access hospitals). However, this preliminary phase 
study is crucial to determining if PWUD will accept 
the technology before deploying this platform to the 
ultimate target users. Furthermore, once feasibility and 
acceptability are established, a suitable billing and 
reimbursement model must be developed in order to 
provide this vital service to communities in need in an 
affordable, sustainable fashion. 
 
6.2. How teleSUDE can be utilized to overcome 
health disparities 
 
Lack of funding and difficulties with transportation 
have been identified as barriers to improving addiction 
care in both urban and rural settings [29]. However, 
these impediments are particularly problematic in 
rural settings, where the populace tends to be less 
affluent and more geographically dispersed, and 
specialized resources for individuals with co-morbid 
conditions such as human immunodeficiency virus 
(HIV) or psychiatric illnesses are scarce [29, 30]. 
Substance use treatment clinicians in rural areas report 
that the scarcity of public transportation combined 
with individuals residing far away from available 
resources creates a scenario where people seeking 
treatment must rely on friends or family members for 
transportation, some of whom have been “enabling or 
using with them,” leading to “additional, more severe, 
and more persistent transportation challenges” [29]. 
Telemedicine is currently being studied as a means 
of creating access to mental health services for 
individuals afflicted by bipolar disorder and post-
traumatic stress disorder residing in rural communities 
where specialist care is unavailable [31]. Similarly, 
teleSUDE seeks to leverage advances in telemedicine 
to bring the expertise of substance use treatment 
specialists based at a tertiary-care academic medical 
center out to our rural communities where some of the 
most disadvantaged populations reside. TeleSUDE 
can ameliorate infrastructure deficiencies by allowing 
PWUD to receive counseling and evaluations within 
the comfort of their residence, obviating the 
potentially costly and time-consuming need to find 
transportation to a distant locale. Additionally, 
teleSUDE clinicians can serve as the centralized 
contact point, helping PWUD in rural areas navigate 
the complexities of the healthcare system and 
coordinating care among the various aspects of 
substance use treatment (e.g., establishing care with 
community-based substance use counseling programs, 
finding openings in supervised detoxification centers, 
and assisting in referrals for the management of co-
occurring medical and psychiatric conditions). 
The overarching goal of teleSUDE is to decrease 
morbidity and mortality from opioid overdose by 
providing a critical intervention during the immediate 
post-overdose period for PWUD residing in low-
resource communities. Historically, this population is 
disproportionately underserved by the healthcare 
system. TeleSUDE will help to level the playing field 
for these individuals, bringing evidence-based 
addiction care across time and distance to areas where 
it is needed most. 
 
6.3. Future directions 
 
Medications for addiction treatment (MAT), 
including buprenorphine and methadone, represent the 
current evidence-based standard of care for the 
treatment of opioid use disorder. Donofrio et al 
showed that initiation of buprenorphine therapy by a 
qualified emergency medicine provider with a plan to 
transition care to an addiction center is more effective 
than behavioral counseling alone in the immediate 
post-overdose period [32]. However ED initiation of 
MAT requires coordination of several resources, 
including licensed providers with a special training 
certification (“X-waiver”), and requires a concerted 
effort even in resource rich environments. While 
further study is necessary to demonstrate the 
generalizability of this approach, ED-initiation of 
MAT via teleSUDE may represent a major 
breakthrough in ED-based post-overdose care, as 
many communities and rural EDs lack providers with 
the requisite certifications to prescribe buprenorphine 
[33].  
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The next step in our work is to use teleSUDE to not 
only link PWUD in underserved areas to addiction 
medicine clinicians, but also to facilitate immediate 
access to MAT with a concrete plan for downstream 
linkage to long-term addiction care. By connecting 
post-overdose patients in rural EDs with specialized 
substance use disorder providers located at a remote 
site, teleSUDE will enhance the ability of EDs to 
perform “warm handoffs” to outpatient substance use 
treatment centers and increase access to much needed 
addiction care resources during the vulnerable post-
overdose period. We envision a world in which 
PWUD in rural Appalachia can receive the same high-
quality addiction care as PWUD in New York City. 
 
7. Conclusions  
 
Our preliminary data suggest that telemedicine 
delivery of substance use disorder evaluations is 
acceptable to patients and intuitive for providers. 
TeleSUDE can enhance access to addiction treatment 
programs and facilitate the efficient and effective 
delivery of evidence-based post-overdose care, 
including ED-based initiation of MAT. Our 
technology platform represents an innovative method 
of delivering treatment for opioid use disorder during 
the critical post-overdose period, and holds immense 
potential for improving access to addiction care for 
PWUD who reside in underserved areas. 
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